15,377 Shares in NewAmsterdam Pharma Company N.V. $NAMS Purchased by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D bought a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 15,377 shares of the company’s stock, valued at approximately $539,000.

A number of other institutional investors have also added to or reduced their stakes in the business. Jennison Associates LLC lifted its position in shares of NewAmsterdam Pharma by 42.5% in the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after purchasing an additional 1,252,451 shares during the period. Atle Fund Management AB boosted its stake in NewAmsterdam Pharma by 23.2% in the third quarter. Atle Fund Management AB now owns 193,625 shares of the company’s stock valued at $5,507,000 after acquiring an additional 36,402 shares in the last quarter. Capital World Investors grew its stake in NewAmsterdam Pharma by 17.1% during the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after buying an additional 1,434,986 shares during the last quarter. Handelsbanken Fonder AB grew its position in NewAmsterdam Pharma by 18.8% during the 3rd quarter. Handelsbanken Fonder AB now owns 405,800 shares of the company’s stock worth $11,541,000 after purchasing an additional 64,200 shares during the last quarter. Finally, Keybank National Association OH purchased a new position in shares of NewAmsterdam Pharma in the third quarter worth $455,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Insider Activity

In other NewAmsterdam Pharma news, Director Louis G. Lange sold 44,619 shares of NewAmsterdam Pharma stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $30.42, for a total transaction of $1,357,309.98. Following the sale, the director owned 10,360 shares of the company’s stock, valued at $315,151.20. The trade was a 81.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael H. Davidson sold 443,707 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the completion of the sale, the chief executive officer owned 174,144 shares of the company’s stock, valued at $5,790,288. This trade represents a 71.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,168,286 shares of company stock worth $38,211,967 over the last 90 days. 12.74% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on NAMS. Truist Financial initiated coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, March 18th. They set a “buy” rating and a $57.00 price objective for the company. Royal Bank Of Canada raised their target price on NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Guggenheim lifted their price target on NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. HC Wainwright upgraded NewAmsterdam Pharma to a “strong-buy” rating in a research note on Thursday, February 19th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $48.00.

NewAmsterdam Pharma Price Performance

NAMS opened at $39.59 on Tuesday. The firm has a fifty day moving average price of $31.95 and a 200 day moving average price of $34.27. NewAmsterdam Pharma Company N.V. has a 1 year low of $16.78 and a 1 year high of $42.21. The stock has a market cap of $4.55 billion, a P/E ratio of -22.12 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The business had revenue of $3.04 million during the quarter. Equities analysts expect that NewAmsterdam Pharma Company N.V. will post -1.81 EPS for the current year.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.